Zimbabwe has rejected a major US health deal worth 367 million US dollars (£272m) spanning five years over the United States' demand for confidential data.
The decision came to light after a internal memorandum dated December was disclosed, indicating that Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
An official representative has since clarified that the US was demanding access to biological samples for research and commercial purposes but refused to guarantee the benefits from any future medical innovations.
"We will now turn to the difficult and regrettable process of scaling back our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the United States had furnished over $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has appealed for continued dialogue to secure a agreement acceptable to all parties so the nation's vital HIV treatment initiative can proceed.
Wider Context
This development comes after a similar case in Kenya, where a court suspended a similar deal with the US following legal challenges were filed about the security of citizens' medical information.
After returning to office recently, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
The agency had overseen aid for the American government, but Trump stated its expenditure was "inefficient" and his government was seeking direct bilateral deals to boost openness and accountability.
According to statements, Sixteen African countries have so far signed these new agreements, constituting over $18.3bn in committed funds.
Specifics of the Rejected Deal
The funds for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration could have provided significant advantages for the people of Zimbabwe, especially the 1.2 million men, women and children presently receiving HIV treatment through American-funded programmes," the Ambassador commented.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"Our nation was requested to share its genetic material and health information indefinitely, without any equivalent guarantee of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," he stated.
"Effectively, our nation would supply the raw materials for scientific discovery without any assurance that the resulting innovations would be accessible to our population if a new disease outbreak emerge."
National Interest and International Frameworks
Mangwana further said that the US's withdrawal from the global health body and its push of bilateral deals were disrupting frameworks previously established via the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing system designed to manage potential global health emergencies.
"This mechanism is intended to ensure that when a nation provides its information, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised solely by those with the funds to develop them."
These objections over the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We encourage further dialogue with our American counterparts on how future collaboration might be arranged in a manner that respects the sovereignty and dignity of each country."
Health Experts Reaction
A leading public health body stated it acknowledged the official position, but urged that talks need to persist since much of the country's HIV programmes relied on foreign aid.
"Where specific concerns exist, such as those involving data governance or agreement terms, these can often be addressed through detailed discussion and negotiated safeguards," the group added.
This impasse underscores the ongoing challenges between receiving much-needed foreign assistance and protecting local interests in an increasingly data-driven world.